Annual report pursuant to Section 13 and 15(d)

Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)

v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Available-for-sale Securities, Total   $ 20,000 $ 87,800  
Debt Securities, Available-for-sale, Total   12,500 36,400  
Finite-lived Intangible Assets Acquired   153,311 0  
Amortization of Intangible Assets, Total   64,940 61,095  
Noncash or Part Noncash Acquisition, Intangible Assets Acquired [1]   4,000 0 $ 0
Patented Technology [Member]        
Finite-lived Intangible Assets Acquired $ 5,000      
Noncash or Part Noncash Acquisition, Intangible Assets Acquired   4,000    
Developed Technology Rights [Member] | Cost of Sales [Member]        
Amortization of Intangible Assets, Total   36,500 34,500 33,300
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]        
Amortization of Intangible Assets, Total   28,400 26,600 $ 25,400
Other Noncurrent Assets [Member]        
Inventory, Finished Goods, Net of Reserves, Non-current   5,456 4,646  
ChemoCentryx, Inc (CCXI) [Member]        
Available-for-sale Equity Securities, Amortized Cost Basis, Total   $ 6,600 $ 6,600  
ChemoCentryx, Inc (CCXI) [Member]        
Share Price (in dollars per share)   $ 13.39 $ 57.54  
[1] $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.